HomeTMCI • NASDAQ
Treace Medical Concepts Inc
$5.77
After Hours:
$5.77
(0.00%)0.00
Closed: Sep 27, 5:20:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$5.80
Day range
$5.74 - $6.07
Year range
$3.92 - $15.98
Market cap
318.41M USD
Avg Volume
582.34K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Jun 2024Y/Y change
Revenue
44.46M5.96%
Operating expense
57.06M20.55%
Net income
-21.21M-72.81%
Net profit margin
-47.70-63.08%
Earnings per share
-0.28-41.25%
EBITDA
-19.27M-61.13%
Effective tax rate
Total assets
Total liabilities
(USD)Jun 2024Y/Y change
Cash and short-term investments
95.05M-31.86%
Total assets
226.08M-9.44%
Total liabilities
113.94M14.30%
Total equity
112.14M
Shares outstanding
62.19M
Price to book
3.22
Return on assets
-22.80%
Return on capital
-28.25%
Net change in cash
(USD)Jun 2024Y/Y change
Net income
-21.21M-72.81%
Cash from operations
-13.90M-66.73%
Cash from investing
22.43M315.23%
Cash from financing
311.00K-73.64%
Net change in cash
8.85M150.33%
Free cash flow
-8.23M2.70%
About
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions. In March 2021, Treace announced its intent to launch an initial public offering. Trading on the Nasdaq under the ticker symbol “TMCI”, Treace opened its IPO in April 2021. Wikipedia
Founded
2014
Website
Employees
516
Search
Clear search
Close search
Google apps
Main menu